Skip to main content

Table 2 Comparison of patient-reported outcomes between the concordant and discordant groups in the prospective substudy

From: Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation

Patient-reported outcome Concordant group
(n = 20)
Discordant groupa
(n = 46)
P value
Pain VAS 25.0 (11.0–42.5) 49.0 (28.0–70.0) .002
SF-MPQ-2 pain score
 Continuous 2.2 (1.8) 3.3 (2.0) .03
 Intermittent 1.8 (2.2) 1.8 (2.0) .71
 Neuropathic 1.2 (1.4) 2.0 (1.8) .045
 Affective 1.1 (1.4) 1.7 (2.0) .06
 Total 1.2 (0.4–2.7) 2.1 (1.2–2.9) .09
Fibromyalgia Research Survey
 WPI 4.5 (2.5–7.0) 7.0 (5.0–10.0) .008
 SS score 3.5 (2.0–5.5) 4.5 (3.0–6.0) .05
 Polysymptomatic distress 7.5 (5.5–12.5) 11.5 (9.0–16.0) .007
BRAF score 5.0 (3.8–5.5) 5.3 (4.3–6.7) .10
PROMIS
 Fatigue 2.4 (1.4–3.4) 2.8 (2.0–3.8) .22
 Pain interference 1.7 (1.3–2.6) 2.2 (1.6–3.1) .04
 Sleep disturbance 2.0 (1.4–3.4) 2.8 (2.0–3.8) .09
 Ability to participate 3.9 (3.4–4.5) 3.5 (3.0–4.1) .06
HAQ-II disability 0.4 (0.1–1.1) 1.0 (0.5–1.4) .003
MAAS 4.6 (4.2–5.3) 5.1 (4.5–5.4) .19
PHQ-9 2.5 (1.0–6.0) 4.0 (3.0–6.0) .18
GAD-7 1.0 (0.0–1.5) 1.0 (0.0–3.0) .12
  1. Values are presented as median (interquartile range)
  2. a Discordant group contains only those patients with patient global assessment greater than physician global assessmen
  3. BRAF Bristol Rheumatoid Arthritis Fatigue, GAD-7 Generalized Anxiety Disorder 7, HAQ-II Health Assessment Questionnaire II, MAAS Mindful Attention Awareness Scale, PHQ-9 Patient Health Questionnaire 9, PROMIS Patient-Reported Outcome Measurement Information System, SF-MPQ-2 Short-Form McGill Pain Questionnaire 2, SS Symptom Severity, VAS visual analog scale, WPI Widespread Pain Index